B6-hALK7 (hACVR1C) Mouse
Product Name
B6-hALK7 (hACVR1C) Mouse
Product ID
C001709
Strain Name
C57BL/6NCya-Acvr1cem1(hACVR1C)/Cya
Backgroud
C57BL/6NCya
When using this mouse strain in a publication, please cite “B6-hALK7 (hACVR1C) Mouse (Catalog C001709) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
Gene Alias
ALK7, ACVRLK7
NCBI ID
Chromosome
Chr 2
MGI ID
Datasheet
Strain Description
The activin A receptor type 1C (ACVR1C), also known as activin receptor-like kinase 7 (ALK7), is a crucial type I serine/threonine kinase receptor belonging to the transforming growth factor-β (TGF-β) superfamily signaling pathway. Upon binding ligands such as activin AB, activin B, and NODAL, ACVR1C initiates intracellular signaling cascades by phosphorylating downstream SMAD2 and SMAD3 transcription factors, thereby regulating diverse cellular processes including cell differentiation, proliferation, apoptosis, and metabolic homeostasis [1]. ACVR1C exhibits a broad expression profile across various tissues, with notable enrichment in adipose tissue, pancreas, heart, and specific brain regions, suggesting its pleiotropic roles in maintaining tissue function [2]. Dysregulation of ACVR1C signaling has been implicated in a range of metabolic disorders, including obesity and type 2 diabetes, as well as in the pathogenesis of certain cancers like retinoblastoma, highlighting its significance as a potential therapeutic target for these conditions [3].
The B6-hALK7 (hACVR1C) mouse is a humanized model constructed using gene editing technology, where the region from aa.27 in exon 2 to partial intron 2 of mouse Acvr1c was replaced with "ACVR1C chimeric CDS-WPRE-BGH pA" cassette. The murine signal peptide of Acvr1c was preserved. This model can be used for studying the pathological mechanisms and therapeutic approaches of metabolic disorders such as obesity and type 2 diabetes, and certain cancers like retinoblastoma, and for the development of ACVR1C-targeted drugs.
Reference
Ibáñez CF. Regulation of metabolic homeostasis by the TGF-β superfamily receptor ALK7. FEBS J. 2022 Oct;289(19):5776-5797.
Zhao M, Okunishi K, Bu Y, Kikuchi O, Wang H, Kitamura T, Izumi T. Targeting activin receptor-like kinase 7 ameliorates adiposity and associated metabolic disorders. JCI Insight. 2023 Feb 22;8(4):e161229.
Asnaghi L, White DT, Key N, Choi J, Mahale A, Alkatan H, Edward DP, Elkhamary SM, Al-Mesfer S, Maktabi A, Hurtado CG, Lee GY, Carcaboso AM, Mumm JS, Safieh LA, Eberhart CG. ACVR1C/SMAD2 signaling promotes invasion and growth in retinoblastoma. Oncogene. 2019 Mar;38(12):2056-2075.
Strain Strategy
The region from aa.27 in exon 2 to partial intron 2 of mouse Acvr1c was replaced with ACVR1C chimeric CDS-WPRE-BGH pA cassette. The murine signal peptide of Acvr1c was preserved.
Figure 1. Gene editing strategy of B6-hALK7 (hACVR1C) mice.
Application Area
ACVR1C-targeted drug screening, development, and evaluation;
Research on the pathological mechanisms and therapeutic approaches of metabolic disorders such as obesity and type 2 diabetes;
Research on the pathological mechanisms and therapeutic approaches of certain cancers like retinoblastoma.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.